Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs American States Water Company (AWR) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
American States Water CompanyTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs American States Water Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while American States Water Company trades at $87.85 (market cap $3.47B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and American States Water Company pays a 2.49% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.

ACADAWR
Market Cap
$5.07B$3.47B
Sector
HealthUtilities
52-Week High
$29.41$89.28
52-Week Low
$20.06$70.10
Enterprise Value
$4.19B$4.37B
Dividend Yield
2.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

American States Water Company

American States Water (AWR) trades at $87.45, up 1.02% with a bullish technical outlook. The company reported strong Q2 2026 earnings of $1.09 per share, beating estimates, driven by water rate increases and revenue growth of 11.2%. Profitability remains robust with a 20.52% net income margin and ROE of 13.62%. Recent news highlights AWR's 71-year dividend growth streak and inclusion in TIME's America's Best Companies 2026 list.

AWR offers stable income with consistent dividend growth but faces valuation concerns at 23.92 P/E. Analyst consensus is cautious with 50% hold ratings. Key risks include regulatory dependence and competitive pressures. The stock presents a defensive play with reliable dividends but limited near-term upside given current multiples.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About American States Water Company

American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.

Read more on AWR